Blockade of epidermal growth factor receptor (EGFR) activity

Antonio Jimeno, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. The key role that EGFR plays in the intracellular transduction of environmental variations and the maintenance of cellular homeostasis explains the dependence that many tumor types have on this pathway, and the pivotal role that it plays in the development of malignant features such as uncontrolled proliferation, augmented invasion, and the ability to escape apoptosis. An enormous body of knowledge has been gathered in the past 20 years that has enabled the development of rationally designed EGFR-targeted therapies, and the results of their clinical evaluation are now becoming available. The lack of positive results of some of these trials has highlighted the need for a robust preclinical knowledge in order to efficiently select patients for therapy, and have prompted the implementation of novel trial designs with rational endpoints.

Original languageEnglish (US)
Pages (from-to)179-192
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume53
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Epidermal Growth Factor Receptor
Drug Discovery
Neoplasms
Homeostasis
Maintenance
Apoptosis
Therapeutics

Keywords

  • EGFR
  • Targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Blockade of epidermal growth factor receptor (EGFR) activity. / Jimeno, Antonio; Hidalgo, Manuel.

In: Critical Reviews in Oncology/Hematology, Vol. 53, No. 3, 03.2005, p. 179-192.

Research output: Contribution to journalArticle

Jimeno, Antonio ; Hidalgo, Manuel. / Blockade of epidermal growth factor receptor (EGFR) activity. In: Critical Reviews in Oncology/Hematology. 2005 ; Vol. 53, No. 3. pp. 179-192.
@article{f44196c8d952463e905496d0509d3e8f,
title = "Blockade of epidermal growth factor receptor (EGFR) activity",
abstract = "The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. The key role that EGFR plays in the intracellular transduction of environmental variations and the maintenance of cellular homeostasis explains the dependence that many tumor types have on this pathway, and the pivotal role that it plays in the development of malignant features such as uncontrolled proliferation, augmented invasion, and the ability to escape apoptosis. An enormous body of knowledge has been gathered in the past 20 years that has enabled the development of rationally designed EGFR-targeted therapies, and the results of their clinical evaluation are now becoming available. The lack of positive results of some of these trials has highlighted the need for a robust preclinical knowledge in order to efficiently select patients for therapy, and have prompted the implementation of novel trial designs with rational endpoints.",
keywords = "EGFR, Targeted therapies",
author = "Antonio Jimeno and Manuel Hidalgo",
year = "2005",
month = "3",
doi = "10.1016/j.critrevonc.2004.10.005",
language = "English (US)",
volume = "53",
pages = "179--192",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Blockade of epidermal growth factor receptor (EGFR) activity

AU - Jimeno, Antonio

AU - Hidalgo, Manuel

PY - 2005/3

Y1 - 2005/3

N2 - The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. The key role that EGFR plays in the intracellular transduction of environmental variations and the maintenance of cellular homeostasis explains the dependence that many tumor types have on this pathway, and the pivotal role that it plays in the development of malignant features such as uncontrolled proliferation, augmented invasion, and the ability to escape apoptosis. An enormous body of knowledge has been gathered in the past 20 years that has enabled the development of rationally designed EGFR-targeted therapies, and the results of their clinical evaluation are now becoming available. The lack of positive results of some of these trials has highlighted the need for a robust preclinical knowledge in order to efficiently select patients for therapy, and have prompted the implementation of novel trial designs with rational endpoints.

AB - The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. The key role that EGFR plays in the intracellular transduction of environmental variations and the maintenance of cellular homeostasis explains the dependence that many tumor types have on this pathway, and the pivotal role that it plays in the development of malignant features such as uncontrolled proliferation, augmented invasion, and the ability to escape apoptosis. An enormous body of knowledge has been gathered in the past 20 years that has enabled the development of rationally designed EGFR-targeted therapies, and the results of their clinical evaluation are now becoming available. The lack of positive results of some of these trials has highlighted the need for a robust preclinical knowledge in order to efficiently select patients for therapy, and have prompted the implementation of novel trial designs with rational endpoints.

KW - EGFR

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=13844255763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844255763&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2004.10.005

DO - 10.1016/j.critrevonc.2004.10.005

M3 - Article

C2 - 15718144

AN - SCOPUS:13844255763

VL - 53

SP - 179

EP - 192

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -